July 16, 2026

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

Conexiant

July 15, 2026

Low IMA Ligation Did Not Significantly Reduce Leaks

A randomized trial found similar short-term morbidity and 12-month functional outcomes with both approaches, while highlighting the need to balance perfusion with a tension-free anastomosis.

Conexiant

July 14, 2026

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.

Conexiant

July 14, 2026

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

Conexiant

July 13, 2026

New CDC Report Tracks US Mortality Trends

The annual provisional report summarizes changes in mortality rates, demographic patterns, and leading causes of death during 2025.

Conexiant

July 10, 2026

FDA Expands Bladder Cancer Regimen

KEYNOTE-B15/EV-304 demonstrated statistically significant improvements in event-free and overall survival with perioperative pembrolizumab plus enfortumab vedotin-ejfv compared with neoadjuvant gemcitabine plus cisplatin.

Conexiant

July 10, 2026

FDA Approves Subcutaneous Isatuximab-irfc

The approval expands subcutaneous use across newly diagnosed and previously treated multiple myeloma.

Conexiant

July 09, 2026

Cancer Screening Gaps Seen in Sexual, Gender Minority Groups

A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.

Conexiant

July 08, 2026

Side Effects: Bro Science, Actually

Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

Conexiant

July 08, 2026

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

Conexiant